Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped. Yahoo Finance host Josh Lipton breaks down the day's top ...

VERX stock could present an entry point as it pulls back to its 10-week moving average. Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

There have been no specific sales or earnings guidance reported for Vertex Pharmaceuticals in recent months. Browse guidance and forecast on all stocks.

It usually doesn't matter if you buy a given stock immediately ... its PDUFA date. Vertex could win approval for suzetrigine early, too. Keith Speights has positions in Vertex Pharmaceuticals.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...